Psoriasis: Causes, Types, Symptoms, and Treatment

You've been told your skin condition is "just cosmetic." You've tried every cream, changed your diet, managed your stress, and still the patches return. The disconnect between doing everything right and seeing no improvement isn't a failure on your part. It's a signal that what's happening on your skin isn't starting there.

Key Takeaways

• Psoriasis is an autoimmune condition driven by immune system dysfunction, not a skin problem.
• The visible plaques are downstream of an inflammatory cascade involving T cells and cytokines.
• Psoriasis shares inflammatory pathways with cardiovascular disease and metabolic syndrome, not just skin.
• Different types of psoriasis reflect different immune triggers and genetic susceptibilities.
• Flares are driven by identifiable triggers including infections, stress, medications, and skin trauma.
• Systemic inflammation markers like hsCRP can reveal cardiovascular risk independent of skin severity.
• Treatment-resistant psoriasis warrants investigation of underlying metabolic and immune drivers.

What Psoriasis Actually Is and Where It Starts

Psoriasis is not a skin disease that happens to involve the immune system. It's an immune-mediated disease that manifests on the skin. The distinction matters because it reframes what you're treating and why topical approaches alone often fall short.

The process begins when dendritic cells in the skin become activated by a trigger, whether that's an infection, physical trauma, or a medication. These activated cells release cytokines, particularly interleukin-23 (IL-23), which in turn activates T helper 17 (Th17) cells. Th17 cells produce IL-17, a pro-inflammatory cytokine that drives keratinocyte proliferation. In healthy skin, keratinocytes take about 28 days to mature and shed. In psoriasis, this process accelerates to 3 to 5 days, creating the thick, scaly plaques characteristic of the condition.

This isn't a localized reaction. The same inflammatory pathways active in the skin are active systemically, which is why psoriasis is increasingly understood as a systemic inflammatory disease rather than a dermatologic one. The visible plaques are the most obvious manifestation, but the underlying immune dysregulation affects vascular health, metabolic function, and joint integrity. Up to 30% of people with psoriasis develop psoriatic arthritis, a condition that reflects the same immune activation targeting different tissues.

How Psoriasis Connects to Systemic Inflammation and Cardiovascular Risk

The immune pathways driving psoriasis don't stop at the skin. Elevated levels of IL-17, tumor necrosis factor-alpha (TNF-α), and IL-23 contribute to endothelial dysfunction, the early stage of atherosclerosis. People with moderate to severe psoriasis have a significantly elevated risk of myocardial infarction, stroke, and atrial fibrillation, independent of traditional cardiovascular risk factors like smoking or hypertension.

Psoriasis is also strongly associated with metabolic syndrome, a cluster of conditions including:

• Insulin resistance, which worsens inflammatory signaling through elevated glucose and insulin levels.
• Elevated triglycerides and low HDL cholesterol, reflecting dyslipidemia driven by systemic inflammation.
• Hypertension, linked to endothelial dysfunction and vascular inflammation.
• Central obesity, where adipose tissue secretes pro-inflammatory cytokines like IL-6 and TNF-α that overlap with psoriasis drivers.

The relationship is bidirectional: systemic inflammation from psoriasis worsens insulin resistance, and insulin resistance amplifies inflammatory signaling, creating a feedback loop that sustains both conditions. The gut-skin axis also plays a role. Emerging research links gut microbiome composition to psoriasis severity. Increased intestinal permeability allows bacterial endotoxins to enter circulation, triggering systemic immune activation. This may explain why some people experience flares in response to dietary changes or gastrointestinal symptoms.

The Different Types of Psoriasis and What They Signal

Psoriasis presents in several distinct forms, each reflecting different immune triggers and genetic susceptibilities. The most common type is plaque psoriasis, accounting for about 80 to 90% of cases. It presents as raised, red patches covered with silvery-white scales, most often on the elbows, knees, scalp, and lower back. Plaque psoriasis can also appear on the face and legs, where the plaques may be thinner and less scaly but still inflamed.

Guttate psoriasis appears as small, drop-shaped lesions scattered across the trunk, arms, and legs. It often follows a streptococcal throat infection, particularly in children and young adults. The immune response to the bacterial infection cross-reacts with skin antigens, triggering the eruption. Guttate psoriasis may resolve on its own or evolve into chronic plaque psoriasis.

Pustular psoriasis is a rarer, more severe form characterized by white pustules surrounded by red skin. The pustules are sterile, meaning they contain white blood cells but not bacteria. Generalized pustular psoriasis can be life-threatening, causing fever, chills, and systemic illness. Localized forms, such as palmoplantar pustulosis, affect the hands and feet and can be debilitating.

Inverse psoriasis affects skin folds, including the armpits, groin, and under the breasts. The plaques are smooth and shiny rather than scaly, and the condition is often worsened by friction and sweating. Erythrodermic psoriasis is the most severe form, covering most of the body with a red, peeling rash. It can disrupt temperature regulation and fluid balance, requiring hospitalization.

Understanding psoriasis vs eczema is important because the two conditions are often confused. While both involve inflammation, eczema is driven by a Th2 immune response with elevated IL-4 and IL-13, leading to a compromised skin barrier and intense itching. Psoriasis, by contrast, is driven by Th17 and Th1 pathways with IL-17 and interferon-gamma, resulting in thickened, scaly plaques. The treatments differ accordingly.

Psoriasis on the face

Psoriasis on face presentations are less common but particularly distressing due to visibility and social impact. Facial psoriasis often involves the hairline, forehead, eyebrows, and the skin between the nose and upper lip. The plaques may be thinner and less scaly than those on the body, but the redness and inflammation are still prominent. Facial involvement can complicate treatment, as the skin on the face is more sensitive to topical steroids and other medications.

Psoriasis on the legs

Psoriasis on legs typically presents as well-defined plaques on the shins, knees, and thighs. The plaques can be thick and resistant to treatment, particularly on the shins where the skin is naturally drier and less responsive to topical therapies. Leg involvement is common in plaque psoriasis and may be accompanied by plaques on other parts of the body.

What Drives Flares and Determines Severity

Psoriasis flares are not random. They reflect identifiable triggers that activate or amplify the underlying immune dysregulation:

• Infections, particularly streptococcal throat infections, trigger immune responses that cross-react with skin antigens.
• Physical trauma to the skin (Koebner phenomenon) initiates local immune activation at injury sites including cuts, scrapes, sunburns, and tattoos.
• Chronic stress elevates cortisol through the HPA axis, leading to immune dysregulation and mast cell activation.
• Certain medications including lithium, beta-blockers, antimalarials, and NSAIDs can trigger or worsen symptoms.
• Alcohol consumption worsens severity through effects on liver function, gut permeability, and systemic inflammation.

Withdrawal from systemic corticosteroids can precipitate a severe flare, including pustular psoriasis. Diet plays a role, though the mechanisms are still being clarified. High glycemic load diets and dairy consumption have been linked to worsening psoriasis in some individuals, possibly through effects on insulin-like growth factor-1 (IGF-1) and inflammatory signaling. Omega-3 fatty acids, found in fish oil, have anti-inflammatory properties and may reduce flare frequency and severity.

Why the Same Condition Looks Different in Different People

Psoriasis severity and presentation vary widely, even among people with the same genetic risk factors. Genetics play a significant role, with certain HLA gene variants, particularly HLA-Cw6, strongly associated with early-onset psoriasis. However, genetics alone don't determine disease expression. Environmental factors, immune phenotype, and metabolic health all shape how psoriasis manifests.

Immune phenotype matters. Some people have a more Th17-dominant response, leading to severe plaque psoriasis, while others have a mixed Th1/Th17 response with different clinical features. Baseline levels of inflammatory cytokines like TNF-α and IL-6 vary between individuals, influencing both disease severity and response to treatment.

Skin microbiome composition also differs. People with psoriasis have altered ratios of Staphylococcus and Streptococcus species on the skin, which can influence local immune activation. Prior antibiotic use, hygiene practices, and environmental exposures all shape the skin microbiome and, by extension, psoriasis severity. Metabolic health is a major determinant of variability. People with obesity, insulin resistance, or metabolic syndrome tend to have more severe psoriasis and poorer treatment responses. Adipose tissue secretes pro-inflammatory cytokines that amplify the immune dysregulation driving psoriasis, creating a vicious cycle.

When Skin Symptoms Point to Something Systemic

Persistent or treatment-resistant psoriasis warrants investigation beyond the skin. Psoriasis is associated with several systemic conditions, and recognizing these connections can guide more effective management.

Cardiovascular disease is the most significant comorbidity. People with psoriasis have elevated rates of coronary artery disease, myocardial infarction, and stroke, driven by shared inflammatory pathways. Elevated hsCRP, a marker of systemic inflammation, is common in psoriasis and independently predicts cardiovascular risk.

Psoriatic arthritis affects up to 30% of people with psoriasis, causing joint pain, stiffness, and swelling. It often develops years after skin symptoms appear, but in some cases, joint symptoms precede skin involvement. Early recognition and treatment are critical to prevent irreversible joint damage. Metabolic syndrome is present in a significant proportion of people with moderate to severe psoriasis. Insulin resistance, elevated triglycerides, low HDL cholesterol, and hypertension are all more common in this population.

Inflammatory bowel disease (IBD), particularly Crohn's disease, shares genetic and immunologic overlap with psoriasis. Both conditions involve dysregulated IL-23 and IL-17 signaling. People with psoriasis who develop gastrointestinal symptoms should be evaluated for IBD. Non-alcoholic fatty liver disease (NAFLD) is more prevalent in people with psoriasis, likely due to shared metabolic and inflammatory drivers. Elevated liver enzymes, particularly ALT and GGT, may signal liver involvement.

What Biomarkers Can Tell You When Topicals Aren't Enough

When psoriasis is persistent, severe, or accompanied by systemic symptoms, biomarker testing can reveal underlying drivers that topical treatments don't address:

• Systemic inflammation markers like hsCRP and ESR reflect immune activation and correlate with cardiovascular risk.
• Metabolic markers including fasting glucose, HbA1c, fasting insulin, and triglyceride-glucose index identify insulin resistance and metabolic syndrome.
• Lipid panels, including apolipoprotein B and lipoprotein(a), provide detailed cardiovascular risk assessment beyond standard cholesterol testing.
• Liver function tests (ALT, AST, GGT) detect NAFLD, which is more common in people with psoriasis.
• Thyroid function tests (TSH, free T3, free T4, thyroid antibodies) identify autoimmune thyroid disease, which co-occurs with psoriasis more often than expected.

Vitamin D levels are worth checking, as vitamin D plays a role in immune regulation and skin cell turnover. Deficiency is common in people with psoriasis and may contribute to disease severity. Zinc and omega-3 fatty acid levels can also be assessed, as both have anti-inflammatory properties relevant to management.

If your psoriasis keeps coming back despite topical treatments, a comprehensive biomarker panel can show you what is happening at the immune, metabolic, and inflammatory level, so your next step is based on data, not guesswork.